Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPROACH: Rosiglitazone vs Glipizide in T2DM Atherosclerosis
NCT00116831Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2005
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of rosiglitazone in type 2 diabetes mellitus (T2DM) and atherosclerosis (2 arms), sponsored by GSK. Primary endpoint: Percent Atheroma Volume at 18 months. Started Jan 2005; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosis
Beyond the preview
Go deeper on NCT00116831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116831.